<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Integrating Epigenetic and Phenotypic Features for Biological Age Estimation in Cancer Patients via Multimodal Learning - Health AI Hub</title>
    <meta name="description" content="This paper introduces EpiCAge, a novel multimodal learning framework that integrates epigenetic and phenotypic data to enhance biological age prediction in canc">
    <link rel="icon" type="image/svg+xml" href="../favicon.svg">
    <link rel="icon" type="image/png" sizes="32x32" href="../favicon-32x32.png">
    <link rel="icon" type="image/png" sizes="16x16" href="../favicon-16x16.png">
    <link rel="stylesheet" href="../styles.css">
</head>
<body>
    <header>
        <div class="container">
            <div class="breadcrumb">
                <a href="../index.html">‚Üê Back to all papers</a>
                <a href="../index.html" class="home-btn">üè† Home</a>
            </div>
        </div>
    </header>

    <main class="container paper-detail">
        <article>
            <h1>Integrating Epigenetic and Phenotypic Features for Biological Age Estimation in Cancer Patients via Multimodal Learning</h1>

            <div class="paper-metadata">
                <div class="meta-row">
                    <strong>arXiv ID:</strong> <a href="http://arxiv.org/abs/2511.07219v1" target="_blank">2511.07219v1</a>
                </div>
                <div class="meta-row">
                    <strong>Published:</strong> 2025-11-10
                </div>
                <div class="meta-row">
                    <strong>Authors:</strong> Shuyue Jiang, Wenjing Ma, Shaojun Yu, Chang Su, Runze Yan, Jiaying Lu
                </div>
                <div class="meta-row">
                    <strong>Categories:</strong> q-bio.GN
                </div>
                <div class="meta-row">
                    <strong>Relevance Score:</strong> 1.00 / 1.00
                </div>
            </div>

            <div class="action-buttons">
                <a href="http://arxiv.org/abs/2511.07219v1" target="_blank" class="btn btn-primary">View on arXiv</a>
                <a href="http://arxiv.org/pdf/2511.07219v1" target="_blank" class="btn btn-primary">Download PDF</a>
            </div>

            <section class="paper-section">
                <h2>Summary</h2>
                <p class="summary-text">This paper introduces EpiCAge, a novel multimodal learning framework that integrates epigenetic and phenotypic data to enhance biological age prediction in cancer patients. EpiCAge consistently outperforms existing age clocks across multiple cancer cohorts, identifies biologically relevant markers, and its derived age acceleration is significantly associated with mortality risk. These findings position EpiCAge as a promising tool for biological age assessment in oncology.</p>
            </section>

            <section class="paper-section">
                <h2>Medical Relevance</h2>
                <p>Accurate biological age assessment in cancer patients offers a deeper understanding of individual aging processes, enabling more personalized risk stratification, optimized treatment planning, and tailored survivorship care strategies to improve patient outcomes.</p>
            </section>

            
            <section class="paper-section">
                <h2>AI Health Application</h2>
                <p>The paper proposes EpiCAge, a multimodal machine learning framework. This AI application integrates epigenetic and phenotypic data to predict biological age in cancer patients. The goal is to provide a more accurate biological age assessment that can be used for clinical decision support, such as risk stratification, personalized treatment planning, and survivorship care in oncology.</p>
            </section>
            

            <section class="paper-section">
                <h2>Key Points</h2>
                <ul class="key-points">
                    
                    <li>Biological age serves as a crucial biomarker for aging processes, informing risk stratification, treatment planning, and survivorship care in cancer patients.</li>
                    
                    <li>The study proposes EpiCAge, a multimodal machine learning framework designed to improve biological age prediction by integrating epigenetic and phenotypic data.</li>
                    
                    <li>EpiCAge was rigorously evaluated across eight internal and four external cancer cohorts, demonstrating robust performance.</li>
                    
                    <li>The framework consistently outperforms existing epigenetic and phenotypic age clocks, indicating superior predictive accuracy.</li>
                    
                    <li>EpiCAge identifies specific biologically relevant markers contributing to the biological age estimation.</li>
                    
                    <li>Age acceleration, as derived by EpiCAge, is significantly associated with increased mortality risk in cancer patients.</li>
                    
                    <li>The research highlights EpiCAge as a promising tool for advanced biological age assessment within oncology.</li>
                    
                </ul>
            </section>

            <div class="two-column">
                <section class="paper-section">
                    <h2>Methodology</h2>
                    <p>EpiCAge is a multimodal machine learning framework that integrates distinct data types: epigenetic features (e.g., DNA methylation) and phenotypic features (e.g., clinical, demographic data). Its performance was validated by comparison against established epigenetic and phenotypic age clocks on eight internal and four external cancer cohorts. Statistical analysis was used to assess the association between EpiCAge-derived age acceleration and mortality risk.</p>
                </section>

                <section class="paper-section">
                    <h2>Key Findings</h2>
                    <p>EpiCAge significantly outperforms current state-of-the-art epigenetic and phenotypic age prediction models. It successfully identifies biologically relevant markers contributing to biological age. Crucially, the age acceleration predicted by EpiCAge is significantly correlated with mortality risk in cancer patients, establishing its prognostic value.</p>
                </section>
            </div>

            <section class="paper-section">
                <h2>Clinical Impact</h2>
                <p>EpiCAge has the potential to revolutionize personalized oncology by providing a more precise biological age assessment. This can lead to improved risk stratification for cancer patients, facilitate more targeted and effective treatment planning based on biological rather than chronological age, and enhance survivorship care strategies, ultimately leading to better patient management and outcomes.</p>
            </section>

            
            <section class="paper-section">
                <h2>Limitations</h2>
                <p>Not explicitly stated in the abstract. However, as with any machine learning model, generalizability across extremely diverse populations or less common cancer types would typically require further validation.</p>
            </section>
            

            
            <section class="paper-section">
                <h2>Future Directions</h2>
                <p>Not explicitly mentioned in the abstract, but the characterization of EpiCAge as a "promising multimodal machine learning tool" implies future work would involve further validation in larger and more diverse cohorts, exploration of its utility across a wider range of cancer types and stages, and potential integration into clinical decision support systems.</p>
            </section>
            

            <section class="paper-section">
                <h2>Medical Domains</h2>
                <div class="tags">
                    
                    <span class="tag">Oncology</span>
                    
                    <span class="tag">Geriatric Oncology</span>
                    
                    <span class="tag">Precision Medicine</span>
                    
                    <span class="tag">Biomarker Discovery</span>
                    
                    <span class="tag">Epigenetics</span>
                    
                    <span class="tag">Prognostics</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Keywords</h2>
                <div class="tags">
                    
                    <span class="tag tag-keyword">Biological age</span>
                    
                    <span class="tag tag-keyword">Cancer</span>
                    
                    <span class="tag tag-keyword">Epigenetics</span>
                    
                    <span class="tag tag-keyword">Phenotype</span>
                    
                    <span class="tag tag-keyword">Multimodal learning</span>
                    
                    <span class="tag tag-keyword">Age acceleration</span>
                    
                    <span class="tag tag-keyword">Mortality risk</span>
                    
                    <span class="tag tag-keyword">Oncology</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Abstract</h2>
                <p class="abstract">Biological age, which may be older or younger than chronological age due to
factors such as genetic predisposition, environmental exposures, serves as a
meaningful biomarker of aging processes and can inform risk stratification,
treatment planning, and survivorship care in cancer patients. We propose
EpiCAge, a multimodal framework that integrates epigenetic and phenotypic data
to improve biological age prediction. Evaluated on eight internal and four
external cancer cohorts, EpiCAge consistently outperforms existing epigenetic
and phenotypic age clocks. Our analyses show that EpiCAge identifies
biologically relevant markers, and its derived age acceleration is
significantly associated with mortality risk. These results highlight EpiCAge
as a promising multimodal machine learning tool for biological age assessment
in oncology.</p>
            </section>

            

            
            <section class="paper-section">
                <h2>Journal Reference</h2>
                <p>In Proceedings of The 19th IEEE International Conference on
  Bioinformatics and Biomedicine (BIBM 2025)</p>
            </section>
            
        </article>
    </main>

    <footer class="container">
        <p><a href="../index.html">‚Üê Back to all papers</a></p>
    </footer>
</body>
</html>